56355-79-4

Usage

Uses

Used in Pharmaceutical Research:
Ethyl 2-(2-bromo-1,3-thiazol-4-yl)acetate is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
As a building block, Ethyl 2-(2-bromo-1,3-thiazol-4-yl)acetate is utilized in the synthesis of a wide range of organic compounds, including heterocyclic compounds, which are important in various chemical and pharmaceutical applications.
Used in Medicinal Chemistry:
Ethyl 2-(2-bromo-1,3-thiazol-4-yl)acetate is employed for its potential pharmacological properties, making it a valuable chemical in the field of medicinal chemistry. Its unique structure and reactivity contribute to the discovery and development of new therapeutic agents.
Used in Chemical Research:
Ethyl 2-(2-bromo-1,3-thiazol-4-yl)acetate is also used in chemical research to explore its reactivity, properties, and potential applications in various chemical reactions and processes, further expanding its utility in the scientific community.

Upstream product

• 53266-94-7 ethyl 2-amino-1,3-thiazol-4-acetate 

Downstream Products

• 62557-07-7 2-(2-bromo-1,3-thiazol-4-yl)acetic acid 
• 120155-43-3 thiazol-4-yl acetic acid ethyl ester 
• 263169-24-0 2-(2-bromothiazol-4-yl)ethanol 
• 917025-42-4 [2-(4-{1-ethyl-1-[3-methyl-4-((E)-4,4,4-trifluoro-3-hydroxy-3-trifluoromethyl-1-butenyl)-phenyl]-propyl}-2-methyl-phenyl)-thiazol-4-yl]-acetic acid ethyl ester 
• 917025-25-3 {2-[4-(1-{4-[3-(t-butyl-dimethyl-silanyloxy)-4,4-dimethyl-pentyl]-3-methyl-phenyl}-1-ethyl-propyl)-2-methyl-phenyl]-thiazol-4-yl}-acetic acid ethyl ester 
• 917025-34-4 {2-[4-(1-{4-[3-(t-butyl-dimethyl-silanyloxy)-4,4-dimethyl-pentyl]-3-methyl-phenyl}-1-ethyl-propyl)-2-methyl-phenyl]-thiazol-4-yl}-acetic acid ethyl ester 
• 917023-38-2 [2-(4-{1-ethyl-1-[3-methyl-4-((E)-4,4,4-trifluoro-3-hydroxy-3-trifluoromethyl-1-butenyl)-phenyl]-propyl}-2-methyl-phenyl)-thiazol-4-yl]-acetic acid 
• 917023-31-5 [2-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methyl-phenyl]-propyl}-2-methyl-phenyl)-thiazol-4-yl]-acetic acid 
• 917023-25-7 [2-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methyl-phenyl]-propyl}-2-methyl-phenyl)-thiazol-4-yl]-acetic acid 
• 913650-49-4 ethyl [2-(5-chloro-2-{[(4-fluorophenyl)methyl]oxy}phenyl)-1,3-thiazol-4-yl]acetate 
• 7504-44-1 thiazol-4-yl acetic acid 
• 1579295-09-2 ethyl 2-(2-(4-phenylbut-1-ynyl)thiazol-4-yl)acetate 
• 1579293-84-7 N-hydroxy-2-(2-(4-phenylbutyl)thiazol-4-yl)acetamide 
• 1579295-11-6 2-(2-(4-phenylbutyl)thiazol-4-yl)acetic acid 

Relevant academic research and scientific papers

4-(2-chloroethyl) thiazole-2-carboxylic acid ethyl ester and preparation method and application thereof

The invention provides 4-(2-chloroethyl) thiazole-2-carboxylic acid ethyl ester and a preparation method and application thereof. The preparation method comprises the steps that 2-(2-aminothiazole-4-yl) ethyl acetate of a compound 1 is dissolved in dichloromethane, and 2-(2-bromothiazole-4-yl) ethyl acetate is obtained through diazotization and halogenation; then, under the condition of a reducing agent, 2-(2-bromothiazole-4-yl) ethane-1-ol is obtained; in a carbon monoxide atmosphere, carbonyl insertion reaction is performed through a proper catalyst to obtain 4-(2-ethoxyl) thiazole-2-carboxylic acid ethyl ester; and finally, thionyl chloride is used for chlorination to obtain 4-(2-chloroethyl) thiazole-2-carboxylic acid ethyl ester. The 4-(2-chloroethyl) thiazole-2-carboxylic acid ethyl ester can be used as an intermediate in synthesis of APJ receptor stimulant compounds. The invention provides a route method for synthesizing the 4-(2-chloroethyl) thiazole-2-carboxylic acid ethyl ester for the first time, the reaction condition is mild after the brominating reagent is optimized in the first step, and the yield is improved.

SHMT INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Oxazolidinone compounds and its use in medicine

The invention relates to an oxazolidinone compound and an application thereof to preparation of drugs for preventing and treating thromboembolic diseases and in particular relates to a compound shown in a general formula (I) in the specification or stereoisomers, geometrical isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound. All the variables are defined in the specification. The invention also relates to an application of the compound shown in the general formula (I) or the stereoisomers, geometrical isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as drugs and in particular relates to an application of the substances as drugs for preventing and treating thromboembolic diseases.

PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS

The present invention provides DNA Gyrase and/or Topo IV inhibitors of Formula (I), which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonus spp., Acenetobacter spp., Mvraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Mycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Cotynebacterium, Bacillus spp., Enterobactericeae (E. coli, Klebsiella spp., Proteus spp., etc.) or any combination thereof. Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections.

PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS

The present invention provides DNA Gyrase and/or Topo IV inhibitors of formula I, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonus spp., Acenetobacter spp., Muraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Mycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Cotyne bacterium, Bacillus spp., Enterobactericeae (E.coli, Klebsiella spp., Proteus spp.,etc.) or any combination thereof Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections

HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is a hydroxylated alkyl group and R9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

VITAMIN D-LIKE COMPOUND

The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable

INDOLE COMPOUNDS

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof; (formula I) wherein X, R1,R2, and R3are as defined in the specification, a process for the preparation of such compounds, pharmaceutical composi

OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS

Compounds of formula (I) or a pharmaceutiically acceptable derivative thereof: wherein X, Z, Y', Y'', R1 ,R2a, R2b, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.